RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+10.59%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$998M
AUM Growth
+$998M
(+2.1%)
Cap. Flow
-$70.6M
Cap. Flow
% of AUM
-7.08%
Top 10 Holdings %
Top 10 Hldgs %
28.11%
Holding
91
New
2
Increased
24
Reduced
43
Closed
3
Top Buys
| 1 |
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
|
$20M |
| 2 |
Cigna
CI
|
$9.22M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$7.15M |
| 4 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$6.77M |
| 5 |
Biogen
BIIB
|
$6.01M |
Top Sells
Sector Composition
| 1 | Healthcare | 91.36% |
| 2 | Financials | 1.12% |
| 3 | Technology | 0.14% |
| 4 | Energy | 0.14% |
| 5 | Communication Services | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cigna
CI
$80.3B
| $36.4M | 3.65% | 174,691 +44,291 | +34% | +$9.22M |
|
2
CVS Health
CVS
$92.8B
| $34.5M | 3.46% | 438,868 +65,000 | +17% | +$5.12M |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $33.8M | 3.39% | 243,329 +51,466 | +27% | +$7.15M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $27.5M | 2.75% | 142,465 -12,535 | -8% | -$2.42M |
|
5
Incyte
INCY
$16.5B
| $26M | 2.61% | 376,916 -6,847 | -2% | -$473K |
|
6
BioMarin Pharmaceuticals
BMRN
$11.2B
| $25.7M | 2.57% | 264,849 +25,000 | +10% | +$2.42M |
|
|
ABMD
7
DELISTED
Abiomed Inc
ABMD
| $25.1M | 2.51% | 55,701 -4,699 | -8% | -$2.11M |
|
8
Medtronic
MDT
$119B
| $24.6M | 2.46% | 249,874 -30,000 | -11% | -$2.95M |
|
9
UnitedHealth
UNH
$281B
| $24.2M | 2.43% | 91,000 -5,000 | -5% | -$1.33M |
|
|
DPLO
10
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $22.8M | 2.28% | 1,174,411 +1,032,047 | +725% | +$20M |
|
11
Exelixis
EXEL
$10.1B
| $22.4M | 2.24% | 1,261,414 +320,200 | +34% | +$5.67M |
|
12
Jazz Pharmaceuticals
JAZZ
$7.75B
| $21.2M | 2.13% | 126,322 -2,114 | -2% | -$355K |
|
13
NovoCure
NVCR
$1.38B
| $21M | 2.1% | 400,000 -50,000 | -11% | -$2.62M |
|
14
Becton Dickinson
BDX
$55.3B
| $20.9M | 2.09% | 80,000 -5,000 | -6% | -$1.31M |
|
15
Bristol-Myers Squibb
BMY
$96B
| $20.5M | 2.05% | 330,000 -110,000 | -25% | -$6.83M |
|
16
Sangamo Therapeutics
SGMO
$157M
| $20.3M | 2.03% | 1,197,357 +145,424 | +14% | +$2.46M |
|
17
Abbott
ABT
$231B
| $19.4M | 1.94% | 264,552 +52,552 | +25% | +$3.86M |
|
18
Elevance Health
ELV
$71.8B
| $19.2M | 1.92% | 70,000 -6,000 | -8% | -$1.64M |
|
19
Nektar Therapeutics
NKTR
$568M
| $18.6M | 1.87% | 305,393 -312,259 | -51% | -$19M |
|
20
Glaukos
GKOS
$5.5B
| $18.3M | 1.83% | 281,279 -78,721 | -22% | -$5.11M |
|
21
Eli Lilly
LLY
$657B
| $18.2M | 1.83% | 170,000 -30,000 | -15% | -$3.22M |
|
|
HZNP
22
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $18M | 1.8% | 917,051 -715,161 | -44% | -$14M |
|
23
Humana
HUM
$36.5B
| $17.9M | 1.8% | 53,000 -20,000 | -27% | -$6.77M |
|
|
SAGE
24
DELISTED
Sage Therapeutics
SAGE
| $17.6M | 1.77% | 124,739 -4,940 | -4% | -$698K |
|
|
ARNA
25
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $16.9M | 1.69% | 366,387 +81,766 | +29% | +$3.76M |
|